All In Biotech

Drug Trial Radar · NCT07364422

To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

A Multicenter, Open-label, Single-arm, Dose-finding and Expansion Phase 1b/2 Study to Evaluate the Safety and Tolerability of JPI-547 in Combination With Irinotecan as a Third Line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

49

Planned (sponsor's estimate)

Start

Feb 27, 2026

Primary completion

Feb 28, 2026

Study completion Feb 28, 2029

Sponsor

Lead sponsor
Onconic Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jan 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety and tolerability of JPI-547 in combination with irinotecan as a third-line and beyond therapy for recurrent or metastatic gastric cancer

Conditions

  • Gastric Cancer (GC)

Interventions

  • JPI-547Drug

    The dose levels will be escalated following a 3+3 dose escalation scheme.

  • Irinotecan (drug)Drug

    The dose levels will be escalated following a 3+3 dose escalation scheme.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1b: dose-limiting toxicity rateTime frame: The dose-limiting toxicity evaluation window is 28 days from C1D1.
  2. phase 2: Overall Response Rate (ORR) according to RECIST v1.1Time frame: At 6-week intervals through study completion, an average of 3 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.